FIRST AMENDMENT TO LEASELease • February 23rd, 2023 • Mannkind Corp • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (the “ Amendment ”) is made as of the 11th day of February 2019 (the “Effective Date ”) by and between BPR 293 EQUITY PARTNERS, LLC , a Massachusetts limited liability company (“Landlord ”), and VALERITAS, INC ., a Delaware corporation (“ Tenant ”).
OFFICE LEASE AGREEMENT BY AND BETWEEN RFP LINCOLN 293, LLC AND VALERITAS, INC. DATED : May 10, 2017Office Lease Agreement • February 23rd, 2023 • Mannkind Corp • Pharmaceutical preparations
This Lease, by and between Landlord and Tenant (as defined below), relates to the space in the building (the “ Building ”) located at 293 Boston Post Road, Marlborough, Massachusetts and known as Boston Post Road Corporate Center. The term “ Lot ” shall mean the parcel of land on which the Building is located, known as Block 77, Lot 11on the Marlborough Tax Map; and the term “ Property ” shall mean the Lot and all improvements thereon from time to time, including the Building.
SECOND AMENDMENT TO COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • February 23rd, 2023 • Mannkind Corp • Pharmaceutical preparations
This amendment is effective the last date signed by a party, between MannKind Corporation, a Delaware corporation (“MannKind”), having a principal place of business at One Casper Street, Danbury, Connecticut 06810, and United Therapeutics Corporation, a Delaware public benefit corporation (“United Therapeutics”), having a principal place of business at 1040 Spring Street, Silver Spring, Maryland 20910.
THIRD AMENDMENT TO COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • February 23rd, 2023 • Mannkind Corp • Pharmaceutical preparations • Maryland
This amendment is effective the last date signed by a party, between MannKind Corporation, a Delaware corporation (“MannKind”), having a principal place of business at One Casper Street, Danbury, Connecticut 06810, and United Therapeutics Corporation, a Delaware public benefit corporation (“United Therapeutics”), having a principal place of business at 1040 Spring Street, Silver Spring, Maryland 20910.
FOURTH AMENDMENT TO COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • February 23rd, 2023 • Mannkind Corp • Pharmaceutical preparations
This amendment is effective the last date signed by a party, between MannKind Corporation, a Delaware corporation (“MannKind”), having a principal place of business at One Casper Street, Danbury, Connecticut 06810, and United Therapeutics Corporation, a Delaware public benefit corporation (“United Therapeutics”), having a principal place of business at 1040 Spring Street, Silver Spring, Maryland 20910.
AMENDMENT NO. 8 TO CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • February 23rd, 2023 • Mannkind Corp • Pharmaceutical preparations • New York
This AMENDMENT NO. 8 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 3rd day of November, 2021, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), QRUMPHARMA, INC., a Delaware corporation (“QP”), TECHNOSPHERE INTERNATIONAL, INC., a Delaware corporation (“Technosphere”, and, Technosphere, together with MannKind, MannKind LLC and QP, each a “Borrower” and collectively, the “Borrowers”), MIDCAP FINANCIAL TRUST, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.
AMENDMENT NO. 9 AND LIMITED CONSENT TO CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • February 23rd, 2023 • Mannkind Corp • Pharmaceutical preparations • New York
This AMENDMENT NO. 9 AND LIMITED CONSENT TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 8th day of November, 2021, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), QRUMPHARMA, INC., a Delaware corporation (“QP”), TECHNOSPHERE INTERNATIONAL, INC., a Delaware corporation (“Technosphere”, Technosphere, together with MannKind, MannKind LLC and QP, each a “Borrower” and collectively, the “Borrowers”), MIDCAP FINANCIAL TRUST, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.
